EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Inhibition of RIPK1 prevents keratinocyte cell death and reduces skin inflammation in type 1–mediated chronic inflammatory skin diseases

Manja Jargosch, Sophia Wasserer, Jessica Eigemann, Theresa Raunegger, Nils Kurzen, Danping Ding-Pfennigdorff, Eckart Bartnik, Carsten B Schmidt-Weber, Tilo Biedermann, Stefanie Eyerich, Kilian Eyerich, Peter Florian und 3 weitere

Journal of Allergy and Clinical Immunology · 2026

DOI: 10.1016/j.jaci.2026.02.006 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Allergy and Clinical Immunology, 2026. Verfasst von Manja Jargosch und 14 weiteren Autor:innen. Beteiligte Einrichtung: Department of Dermatology and Allergy, Technical University of Munich, Munich, Germany; Center of Allergy and Environment (ZAUM), Technical Universit…. Hauptthemen laut MEDLINE: Receptor-Interacting Protein Serine-Threonine Kinases, Keratinocytes, Lichen Planus. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 48 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Sanofi-Aventis Deutschland GmbH, Technische Universität München.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: Type 1-mediated chronic inflammatory skin diseases affect skin, hair, nails, and mucosa and dramatically impact patients' quality of life. The 2 most prominent examples are lichen planus (LP) and cutaneous lupus erythematosus (CLE). Various cell death pathways are activated in both diseases, including apoptosis and necroptosis. RIPK1 is a key regulator of programmed cell death and thus represents a potential new target for treatment of these diseases. OBJECTIVE: We sought to determine the impact of RIPK1 on cell death and inflammation in LP and CLE. METHODS: RNA sequencing of inflammatory skin diseases (n = 179) assessed cell death, hypothermia, and inflammatory markers affected by eclitasertib, a novel RIPK1 inhibitor, in human cells, murine TNF-α-induced systemic inflammatory response syndrome model, reconstructed human epidermis, and ex vivo skin biopsy culture. RESULTS: Markers of apoptosis (CASPASE8) and necroptosis (RIPK3, MLKL) are upregulated in LP and CLE. Eclitasertib restored body temperature when orally administered 15 minutes after TNF-α injection in the murine systemic inflammatory response syndrome model. RIPK1 inhibition prevented keratinocyte cell death; normalized epidermal architecture; and decreased release of IL-1α, IL-1β, TNF-α, and CCL20 in reconstructed human epidermis on stimulation with LP and CLE T-cell supernatant. Ex vivo culture of LP and CLE biopsy specimens with eclitasertib reduced expression of disease-specific genes and downregulated pathways associated with inflammation. CONCLUSIONS: Inhibition of RIPK1 targets 2 major pathogenic events in LP and CLE: epidermal cell death and type 1-mediated skin inflammation.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Receptor-Interacting Protein Serine-Threonine KinasesKeratinocytesLichen PlanusHumansAnimalsMiceCell DeathTumor Necrosis Factor-alphaApoptosisSkinInflammation

Stichwörter der Autor:innen

Lichen planusRIPK1cell deathcutaneous lupus erythematosuseclitasertibnecroptosistargeted therapy

Substanzen

Receptor-Interacting Protein Serine-Threonine KinasesRIPK1 protein, humanRipk1 protein, mouseTumor Necrosis Factor-alpha

Autor:innen und Institutionen

  • Department of Dermatology and Allergy, Technical University of Munich, Munich, Germany; Center of Allergy and Environment (ZAUM), Technical University of Munich and Helmholtz Zentrum Munich, Munich and Neuherberg, Membe…
  • Department of Dermatology and Allergy, Technical University of Munich, Munich, Germany.
  • Department of Dermatology and Allergy, LMU Hospital, Munich, Germany.
  • Immunology and Inflammation Therapeutic Area, Sanofi R&D, Sanofi, Frankfurt am Main, Germany.
  • Center of Allergy and Environment (ZAUM), Technical University of Munich and Helmholtz Zentrum Munich, Munich and Neuherberg, Member of the German Center of Lung Research (DZL), Neuherberg, Germany.
  • Center of Allergy and Environment (ZAUM), Technical University of Munich and Helmholtz Zentrum Munich, Munich and Neuherberg, Member of the German Center of Lung Research (DZL), Neuherberg, Germany; Institute for Immuno…

Förderung

  • Sanofi-Aventis Deutschland GmbH
  • Technische Universität München

Zitieren

APA

Jargosch, M., Wasserer, S., Eigemann, J., Raunegger, T., Kurzen, N., Ding-Pfennigdorff, D., Bartnik, E., Schmidt-Weber, C. B., Biedermann, T., Eyerich, S., Eyerich, K., Florian, P., Herrmann, M., Saas, J., & Lauffer, F. (2026). Inhibition of RIPK1 prevents keratinocyte cell death and reduces skin inflammation in type 1–mediated chronic inflammatory skin diseases. Journal of Allergy and Clinical Immunology. https://doi.org/10.1016/j.jaci.2026.02.006

Vancouver

Jargosch M, Wasserer S, Eigemann J, Raunegger T, Kurzen N, Ding-Pfennigdorff D, et al. Inhibition of RIPK1 prevents keratinocyte cell death and reduces skin inflammation in type 1–mediated chronic inflammatory skin diseases. Journal of Allergy and Clinical Immunology. 2026. doi:10.1016/j.jaci.2026.02.006

BibTeX
@article{Jargosch2026,
  author = {Jargosch, Manja and Wasserer, Sophia and Eigemann, Jessica and Raunegger, Theresa and Kurzen, Nils and Ding-Pfennigdorff, Danping and Bartnik, Eckart and Schmidt-Weber, Carsten B and Biedermann, Tilo and Eyerich, Stefanie and Eyerich, Kilian and Florian, Peter and Herrmann, Matthias and Saas, Joachim and Lauffer, Felix},
  title = {Inhibition of RIPK1 prevents keratinocyte cell death and reduces skin inflammation in type 1–mediated chronic inflammatory skin diseases},
  journal = {Journal of Allergy and Clinical Immunology},
  year = {2026},
  doi = {10.1016/j.jaci.2026.02.006}
}
Kostenlos starten →